Aardvark Therapeutics Inc... (AARD)

NasdaqGS: AARD · Real-Time Price · USD

6.54

+0.13 (2.03%)

At close: Aug 14, 2026, 3:59 PM

6.54

+0.00%

After-hours: 7:34 PM

Statistics

Share Statistics

Aardvark Therapeutics has 21.88M shares outstanding. The shares have a market value of 143.13M.

Shares Outstanding	21.88M
Shares Change (YoY)	-8.23%
Shares Change (QoQ)	0.15%
Owned by Institutions (%)	48.79%
Shares Floating	10.98M
Failed to Deliver (FTD) Shares	14
FTD / Avg. Volume	n/a

Short Selling Information

Short interest in Aardvark Therapeutics is 2.98% of the outstanding shares, representing 652.5K shares. The short ratio is 1.7.

Short Interest	652.5K
Short % of Shares Out	2.98%
Short % of Float	4.46%
Short Ratio (days to cover)	1.7

Valuation Ratios

PE Ratio	n/a
Forward PE	-2.35
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.91
P/FCF Ratio	-2.32
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The enterprise value is 69.93M. Enterprise value adds debt and subtracts cash from the company's market cap, providing an alternative valuation for the company.

EV / Sales	n/a
EV / EBITDA	-0.95
EV / EBIT	-1.13
EV / FCF	-1.13

Financial Position

Aardvark Therapeutics's current ratio is 12.63. A current ratio above 1 means that the company has enough short-term assets to cover its short-term liabilities.

Current Ratio	12.63
Quick Ratio	11.57
Debt / Equity	0
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage

Financial Efficiency

Return on Equity is -66.02%, and return on invested capital is -85.57%.

Return on Equity	-66.02%
Return on Assets	-40.38%
Return on Invested Capital	-85.57%
Revenue Per Employee	n/a
Profits Per Employee	$-2.5M
Employee Count	28
Asset Turnover	0
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by -38.6% in the past year.

Beta
52-Week Price Change	-38.6%
50-Day Moving Average	5.61
200-Day Moving Average	8.29
Relative Strength Index (RSI)	48.75
Average Volume (20 Days)	261,754

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-74.72M
Net Income	-69.87M
EBITDA	-74.68M
EBIT	-74.72M
Earnings Per Share (EPS)	-3.31

Full Income Statement

Balance Sheet

Aardvark Therapeutics has 62.44M in cash on the balance sheet. Total assets are 98.59M, and total liabilities are 336K.

Cash & Cash Equivalents	62.44M
Total Debt	336K
Net Cash	62.1M
Retained Earnings	-137.51M
Total Assets	98.59M
Working Capital	81.98M

Full Balance Sheet

Cash Flow

Aardvark Therapeutics's operating cash flow was -61.65M over the trailing twelve months.

Operating Cash Flow	-61.65M
Capital Expenditures	n/a
Free Cash Flow	-61.75M
FCF Per Share	-2.821

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	0%
Earnings Yield	-50.61%
FCF Yield	-43.14%

Dividend Details

Analyst Forecast

According to 10 stock analysts, the average 12-month price target for Aardvark Therapeutics is $6.5. The average analyst rating is "Buy".

Price Target	$6.5
Price Target Difference	-0.61%
Analyst Consensus	Buy
Analyst Count	10

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the fair value of a stock, including the Graham Number and Lynch Fair Value methods.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	3.94
Piotroski F-Score	3